Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of ADI-PEG 20 in Malignant Pleural Mesothelioma
2006-004592-35Phase 2Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pleural mesothelioma comparing ADI-PEG 20 + Best Supportive Care with Best Supportive Care Only (2 arms). Primary endpoints: Rate of progression or death at 6 months and Time to disease progression. Started Jun 2010; status: completed.
02
Drugs
Pegargiminase
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2006-004592-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004592-35.